Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody
Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
1 . A method for treating, reducing the severity of, slowing progression of, or inhibiting accelerated atherosclerosis in a subject in need thereof, comprising:
administering to the subject an effective amount of an antibody or antibody fragment comprising a heavy chain complementarity determining region (HCDR) 1 having the sequence of SEQ ID NO: 2, an HCDR 2 having the sequence of SEQ ID NO: 3, and an HCDR 3 having the sequence of SEQ ID NO: 4, a light chain complementarity determining region (LCDR) 1 having a sequence of SEQ ID NO: 5, an LCDR 2 having a sequence of SEQ ID NO: 6, and an LCDR 3 having a sequence of SEQ ID NO: 7, wherein the subject has symptoms of rheumatoid arthritis or has been diagnosed with rheumatoid arthritis.
2 . The method of claim 1 , wherein the antibody comprises the variable heavy region (VH) of SEQ ID NO: 8, the variable light region (VL) of SEQ ID NO: 9, or both.
3 . The method of claim 2 , wherein the antibody comprises the heavy chain of SEQ ID NO: 10, the light chain of SEQ ID NO: 11, or both.
4 . The method of claim 1 , wherein the antibody is orticumab.
5 . The method of claim 4 , wherein the antibody or antibody fragment is administered in one, two or more doses of at least 5 mg/kg each or at least 8 mg/kg each.
6 . The method of claim 5 , further comprising administering a plurality of subsequent doses of the antibody or antibody fragment in an amount of at least 2 mg/kg/week, at least 2.5 mg/kg/two weeks, or at least 6 mg/kg/month.
7 . The method of claim 5 , wherein two or more doses are administered, and wherein the two or more doses are administered over at least 8 weeks, 10 weeks, or 12 weeks.
8 . The method of claim 4 , wherein the antibody is administered at 1-10 μg/kg, 10-100 μg/kg, 100-500 μg/kg, 200-500 μg/kg, 300-500 μg/kg, 400-500 μg/kg, 1-5 mg/kg, 5-10 mg/kg, 10-15 mg/kg, 15-20 mg/kg, 20-25 mg/kg, 25-50 mg/kg, or 50-75 mg/kg.
9 . The method of claim 1 , further comprising administering a therapeutic agent selected from the group consisting of azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine sulfate, leflunomide, methotrexate, mycophenolate mofetil, sulfasalazine, bis-phenyl (2-halophenyl)-1-imidazolylmethane, clotrimazole, tinidazole, nitroimidazole, 4-aminoquinolines, hydroxychloroquine, amodiaquine, copper sulphate, dehydrocholine, clotrimazole, suramin, pentamidine, dehydroemetine, metronidazole, nimorazole, phanquone, diloxanide, an anti-tumor necrosis factor (TNF) antibody, an anti-TNF peptide, and a nucleic acid encoding an anti-TNF antibody or peptide.
10 . The method of claim 1 , further comprising selecting a subject showing a symptom of or having been diagnosed with rheumatoid arthritis, prior to administering the effective amount of the antibody or antibody fragment thereto.
11 . The method of claim 1 , wherein the subject has an elevated amount of one or more markers of inflammation in circulation selected from the group of tumor necrosis factor-alpha (TNFα), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), monocyte chemoattractant protein-1, and C-reactive protein (CRP), compared to a control subject free of accelerated atherosclerosis.
12 . The method of claim 1 for treating, reducing the severity of, slowing progression of, or inhibiting a combination of rheumatoid arthritis and accelerated atherosclerosis.